Previous 10 | Next 10 |
Immunic (NASDAQ:IMUX) stock lost over 60% of its value on June 2 premarket after the company said its lead asset vidofludimus calcium (IMU-838) failed a phase 2 trial in ulcerative colitis (UC) and that it will not plans further development in UC without a partner. The pha...
Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update PR Newswire – Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Popu...
The following slide deck was published by Immunic, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Immunic, Inc. 2022 Q1 - Results - Earnings Call Presentation
Immunic Inc. (IMUX) Q1 2022 Earnings Conference Call May 10, 2022, 8:00 AM ET Company Participants Daniel Vitt – Chief Executive officer, President & Director Glenn Whaley – Vice President of Finance and Principal Financial & Accounting Officer Conference Call Participan...
Immunic press release (NASDAQ:IMUX): Q1 GAAP EPS of -$0.74 beats by $0.05. Cash and Cash Equivalents as of March 31, 2022 were $95.7 million, which does not include the additional $10.0 million of net proceeds raised in April 2022 under the company's at-the-market sales agreement. As a result...
Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire – Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis Expected Next Month – – Part ...
ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS, EBIX, ENOV, EOSE, EPC, EPZM, EVRI, FOX, FOXA, GMDA, H, HAE, HL, IAA, IGT, IIVI, IMUX, ITCI, JAGX, OTCPK:KEYUF, KNBE,...
Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease PR Newswire – First Time Patients Will be Treated with the Company's Orally Available Small Molecule Modulator Targeting Restoration of Intestinal Barrier Funct...
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on May 10, 2022 – NEW YORK , May 3, 2022 /PRNewswire/ -- Immunic, In...
Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences PR Newswire NEW YORK , April 25, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral...
News, Short Squeeze, Breakout and More Instantly...
Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President,...
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...